Drug Profile
Estradiol-transdermal - Noven
Alternative Names: Femiest; Menorest; VivelleLatest Information Update: 28 Aug 2009
Price :
$50
*
At a glance
- Originator Noven Pharmaceuticals
- Developer Novartis; Noven Pharmaceuticals; Novogyne Pharmaceuticals; Sanofi; Yakult Honsha
- Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Menopausal syndrome; Postmenopausal osteoporosis
Most Recent Events
- 20 Aug 2013 Biomarkers information updated
- 27 Aug 2009 Noven Pharmaceuticals has been acquired by Hisamitsu Pharmaceutical
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis